✦ LIBER ✦

A Risk-Benefit Assessment of Amifostine in Cytoprotection

✍ Scribed by May Mabro, Sandrine Faivre, Dr Eric Raymond

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Risk-Benefit Assessment of Antileukotr

✍ Dr Lewis J. Smith 📂 Article 📅 1998 🏛 Springer International Publishing AG 🌐 English ⚖ 187 KB

A Risk-Benefit Assessment of Abciximab i

✍ Dr Neal S. Kleiman 📂 Article 📅 1999 🏛 Springer International Publishing AG 🌐 English ⚖ 172 KB

Hypofractionated and accelerated radioth

✍ M.I. Koukourakis; C. Kouroussis; S. Kakolyris; A. Giatromanolaki; E. Sivridis; C 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 193 KB

The effect of amifostine, a cytoprotecti

✍ Brandon K. Wills; Steven E. Aks; Gerry E. Maloney; James W. Rhee; Rhonda Brand; 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 282 KB

Benefit/risk assessment in clinical rese

✍ Peter R. Kowey; Ted D. Friehlng; Roger A. Marinchak 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 194 KB

Benefit-Risk Assessment of Leflunomide

✍ Nicola Alcorn, Sarah Saunders, Dr Rajan Madhok 📂 Article 📅 2009 🏛 Springer International Publishing AG 🌐 English ⚖ 228 KB